Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBUILD-2 galcanezumab study in adolescents with chronic migraine
2018-004622-28Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine headache days. Started Sep 2020; status: active.
02
Drugs
galcanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2018-004622-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004622-28.